Cross-sectional and prospective relationships of apoA-I and apoB100 with subclinical atherosclerosis

apoA-I 和 apoB100 与亚临床动脉粥样硬化的横断面和前瞻性关系

• 批准号: 17K15826
• 负责人: ZAID MARYAM
• 金额: $ 1.75万
• 依托单位: Shiga University of Medical Science
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2017
• 资助国家: 日本
• 起止时间: 2017-04-01 至 2020-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17K15826/
• 关键词: apoA1; apoB; atherosclerosis; apoA-I; apoB100; epidemiology

We have fully completed our study on serum measurements of apoA1 and apoB and subclinical atherosclerosis. We have found that both apoA1 and apoB have significant relationships with carotid intima-media thickness, a marker of subclinical atherosclerosis. These relationships, however, are dependent on their lipid counterparts: HDL-P and LDL-P.In our longitudinal analyses, we could not find any significant relationship between the changes in apoprotein levels and evidence of clinical improvements in coronary subclinical atherosclerosis. Neither apoA1, nor apoB was significantly related to changes in total agatston score.We are currently in the manuscript write-up stage of this study. We hope to soon submit to International SCI journals, such as Atherosclerosis, ATVB and Heart.

我们已经完全完成了血清载脂蛋白A1和载脂蛋白B测定与亚临床动脉粥样硬化的研究。我们发现载脂蛋白A1和载脂蛋白B都与颈动脉内膜-中层厚度显著相关，颈动脉内膜-中层厚度是亚临床动脉粥样硬化的标志。然而，这些关系依赖于他们的脂质对应物：高密度脂蛋白-P和低密度脂蛋白-P。在我们的纵向分析中，我们没有发现载脂蛋白水平的变化与冠状动脉亚临床动脉粥样硬化临床改善的证据之间有任何显著的关系。载脂蛋白A1和载脂蛋白B与Agatston总分的变化均无明显关系。我们目前正处于这项研究的手稿撰写阶段。我们希望尽快提交给国际SCI期刊，如动脉粥样硬化，ATVB和心脏。